|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||12.30 - 13.48|
|52 Week Range||0.25 - 50.00|
|Beta (5Y Monthly)||-4.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company") capital formation plan, the Company has obtained, received and segregated all funds necessary to execute the first phase of the development project of a nanoemulsion of dactinomycin, with the initial tranche released as scheduled.
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc.